Your search history is turned on.
Date: April 8, 2024 Jurisdictions: Alberta, British Columbia, Ontario
24-10646-1_ESSA Pharma Inc._S-8 - AsFiled.pdf As filed with the Securities and Exchange Commission on April 5, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ESSA PHARMA INC. (Exact name of registrant as specified in its charter) Br...
Date: March 7, 2024 Jurisdictions: Alberta, British Columbia, Ontario
ESSA Pharma Inc. (the Company) Annual General Meeting of Shareholders (the Meeting) March 6, 2024 REPORT OF VOTING RESULTS (Pursuant to Section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations) Common shares of the Company (the Common Shares) represented at the Meeting: 33,428,657 Total issued and outstandi...
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS South San Francisco, USA and Vancouver, Canada, March 7, 2024 ESSA Pharma Inc. (ESSA or the Company) (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes...
Date: February 13, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Exhibit 32.1 CERTIFICATION OF CEO AND CFO PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the quarterly report of ESSA Pharma Inc. (the "Registrant") filed under cover of Form 10-Q for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), David Parkinson as Chie...
Exhibit 31.2 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David Wood, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of ESSA Pharma Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh...
Exhibit 31.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David Parkinson, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of ESSA Pharma Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in...
22 Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations The following discussion should be read in conjunction with the attached financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q, as well as our audited financial statements and related notes thereto and managements discu...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio...
8 PART I. FINANCIAL INFORMATION Item 1. Financial Statements and Supplementary Data ESSA Pharma Inc. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited) (Expressed in United States dollars) FOR THE THREE MONTHS ENDED DECEMBER 31, 2023 9 ...
1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achieving PSA90, 69% of patients ...